Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
Recent reports highlighting serious adverse effects of antipsychotic medication in behavioral and psychological symptoms of dementia (BPSD) has led to calls for research on alternative agents. The authors describe the use of low-dose gabapentin to treat seven patients with a diagnosis of ICD-10 vascular or Mixed Vascular/Alzheimer Dementia with serious aggressive behavior. All seven patients Originally developed for treatment of epi- lepsy, gabapentin (NbN: glutamate: voltage-gated calcium chan- nel blocker) has only case reports and case series suggesting effectiveness for BPSD symptoms, covering agitation and aggression, with or without sexual disinhibition (Kim et al., 2008). Several case reports describe using gabapentin, an anti-epileptic and FDA-approved treatment for neuropathic pain, as an off-label treatment for BPSD. BPSD in some patients may be driven by unreported neuropathic pain, which gabapentin can treat effectively. Additionally, gabapentin has known anxiolytic properties that can theoretically improve Recent reports highlighting serious adverse effects of antipsychotic medication in behavioral and psychological symptoms of dementia (BPSD) has led to calls for research on alternative agents. The authors describe the use of low-dose gabapentin to treat seven patients with a diagnosis of ICD-10 vascular or Mixed Vascular/Alzheimer Dementia with serious aggressive behavior. All seven patients In most of the reviewed cases, gabapentin was reported to be a well tolerated and effective treatment for BPSD. However, two case reports in which gabapentin was used in the context of agitation in dementia with Lewy bodies questioned the appropriateness of gabapentin for all types of dementia-related agitation. Objective: To review and summarize the currently available data on the use of anticonvulsant mood stabilizers (carbamazepine, valproic acid, gabapentin, lamotrigine, topiramate) in the treatment of behavioral and psychological symptoms of dementia (BPSD); to determine whether these medications can be recommended for routine clinical use.Methods: Literature search in five databases (PubMed The manuscript presents 11 community dwelling elderly patients affected by moderate – severe DLB treated with gabapentin (GBP) for BPSD. Despite absence of large controlled studies with GBP in BPSD, this pharmaceutical is a part of the treatment algorithm in Canada [7]. GBP attracts clinicians with its safety and tolerability. Additionally, gabapentin has known anxiolytic properties that can theoretically improve BPSD. A 2018 systematic review by Supasitthumrong et al highlights data supporting the use of gabapentin as a treatment for BPSD, but noted there has yet to be a definitive trial establishing gabapentin as an effective intervention for BPSD. We would like to show you a description here but the site won’t allow us. Abstract Objective: To report the use of gabapentin in the treatment of behavioral and psychological symptoms of dementia (BPSD) and to review the available literature relating to the use of gabapentin in this population. Pain, gabapentin, & BPSD “Pain often leads to BPSD of various types, such as insomnia, aggressiveness or agitation,” note Tible et al. Detecting pain, diagnosing causes, and treating pain can be an important clinical strategy in dementia care, they explain. (Read about how to recognize pain in a patient with dementia.) Conclusion Gabapentin and pregabalin could be considered for BPSD when medications having stronger evidence bases (risperidone, other antipsychotics, carbamazepine and citalopram) have been ineffective or present unacceptable risks of adverse outcomes. Gabapentin has the potential to be particularly helpful if the BPSD symptoms are in the context of neuropathic pain. Evidence for its use is supported by 14 case reports that showed positive Recent reports highlighting serious adverse effects of antipsychotic medication in behavioral and psychological symptoms of dementia (BPSD) has led to calls for research on alternative agents. The authors describe the use of low-dose gabapentin to treat seven patients with a diagnosis of ICD-10 vascular or Mixed Vascular/Alzheimer Dementia with serious aggressive behavior. All seven patients Gabapentin and pregabalin could be considered for BPSD when medications having stronger evidence bases (risperidone, other antipsychotics, carbamazepine and citalopram) have been ineffective or present unacceptable risks of adverse outcomes. Gabapentin and pregabalin could be considered for BPSD when medications having stronger evidence bases (risperidone, other antipsychotics, carbamazepine and citalopram) have been ineffective or present unacceptable risks of adverse outcomes. Several case reports describe using gabapentin, an anti-epileptic and FDA-approved treatment for neuropathic pain, as an off-label treatment for BPSD. BPSD in some patients may be driven by unreported neuropathic pain, which gabapentin can treat effectively. Additionally, gabapentin has known anxiolytic properties that can theoretically improve Discover the efficacy of gabapentin for treating behavioral and psychological symptoms of dementia (BPSD) in a retrospective chart review. Findings suggest gabapentin as a safe option in combination with antipsychotic medications or as monotherapy for certain BPSD patients. Conclusions: Gabapentin may be a safe option for the treatment of BPSD in combination with antipsychotic medications. Gabapentin may also be effective as monotherapy in certain patients with BPSD. Especially in older adults, gabapentin and pregabalin are prescribed to treat behavioral and psychological symptoms of dementia (BPSD). A systematic review analyzing 24 relevant articles found that the use of gabapentinoid agents significantly decreased BPSD in patients with Alzheimer’s disease, suggesting a possible benefit.
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |